Table 1 Demographic and clinical characteristics of patients with and without cholestasis.

From: Presence of cholestasis and its impact on survival in SARS-CoV-2 associated acute respiratory distress syndrome

Variable

All patients

Cholestasis

No cholestasis

P

n (%)

225

119 (53)

106 (47)

 

Male, n (%)

154 (68)

79 (66)

75 (71)

0.575

Age (years), mean (SD)

56.2 (12.1)

57.1 (9.8)

55.2 (14.3)

0.248

BMI, kg/m2 mean (SD)

32 (7.5)

31.4 (6.3)

32.8 (8.7)

0.156

Comorbidities

    

Diabetes, n (%)

67 (30)

40 (34)

27 (25)

0.235

Obesity, n (%)

100 (44)

53 (44)

48 (45)

0.917

Arterial hypertension, n (%)

128 (57)

72 (61)

56 (53)

0.305

Chron. lung disease, n (%)

30 (13)

16 (13)

14 (13)

0.999

Chron. liver disease, n (%)

18 (8)

12 (10)

6 (6)

0.33

Chron. kidney disease, n (%)

18 (8)

12 (10)

6 (6)

0.33

SOFA, median (IQR)

8 (7–10)

8 (7–10)

8 (7–10)

0.304

SAPSII, median (IQR)

41 (34–51)

40 (34–46)

43 (33–53)

0.12

APACHEII, median (IQR)

19 (14–22)

18 (15–23)

19 (13–22)

0.889

P/F ratio nadir, median (IQR)

60 (52–71)

57 (50–65)

64 (53–76)

0.001

ICU LOS (days), median (IQR)

30 (15–50)

40 (28–66)

18 (8–31)

< 0.001

28-day survival, n (%)

167 (74)

87 (73)

80 (75)

0.801

ICU survival, n (%)

141 (63)

66 (55)

75 (71)

0.026

6-month survival, n (%)

132 (59)

61 (51)

71 (67)

0.024

IMV, n (%)

210 (93%)

118 (99%)

92 (87%)

< 0.001

IMV (days), median (IQR)

28 (12–45)

38 (24–58)

15 (7–29)

< 0.001

Prone position, n (%)

177 (79)

100 (85)

77 (73)

0.055

Prone position (days), median (IQR)

4 (1–8)

5 (2–9)

3 (0–6)

< 0.001

ECMO, n (%)

130 (58)

93 (78)

37 (35)

< 0.001

ECMO (days), median (IQR)

23 (13–35)

25 (14–36)

15 (10–34)

0.114

Norepinephrine, n (%)

209 (93)

117 (98)

92 (87)

0.002

Norepinephrine (days), median (IQR)

12 (6–26)

19 (9–32)

7 (2–15)

< 0.001

Vasopressin, n (%)

38 (17)

23 (19)

15(14)

0.392

Dobutamine, n (%)

34 (15)

20 (17)

14 (13)

0.571

Ketamine, n (%)

184 (82%)

111 (93)

73 (69)

< 0.001

Ketamine (days), median (IQR)

10 (3–17)

14 (9–21)

6 (0–11)

< 0.001

Neuromuscular blockade, n (%)

144 (64)

87 (73)

57 (54)

0.004

Neuromuscular blockade (days), median (IQR)

2 (0–5)

3 (0–7)

2 (0–4)

< 0.001

Parenteral nutrition, n (%)

149 (66)

90 (76)

59 (56)

0.003

Parenteral nutrition (days), median (IQR)

5 (0–11)

7 (2–15)

2 (0–7)

< 0.001

UDCA, n (%)

107 (48)

87 (73)

20 (19)

< 0.001

UDCA (mg/kg BW), median (IQR)

15 (10–18)

15 (11–18)

11 (7–16)

0.009

  1. n., number of patients; %, percent; IQR, interquartile range; SD, standard deviation; SOFA, Sequential Organ Failure Assessment Score; SAPSII, Simplified Acute Physiology Score II; APACHEII, Acute Physiology and Chronic Health Evaluation II Score; P/F ratio, PaO2/FiO2; ICU, intensive care unit; LOS, length of stay; IMV, invasive mechanical ventilation; ECMO, extracorporeal membrane oxygenation; UDCA, ursodeoxycholic acid; BW, body weight.
Back to article page